Work

Immunotherapy to prevent progression on active surveillance study (IPASS): A phase II, randomized, double-blind, controlled trial of PROSTVAC in prostate cancer patients who are candidates for active surveillance.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.6_suppl.249

Authors: J Kellogg Parsons, Peter A. Pinto, Howard L. Parnes, Christian P. Pavlovich, Edward M. Uchio, Mike Minh Nguyen, Hyung Lae Kim, James L. Gulley, Houssein Abdul Sater, Christina Jamieson, Chiu-Hsieh Hsu, Malgorzata E. Wojtowicz, Jeffrey Schlom, Renee Nicole Donahue, Sara Centuori, Shania Bailey, Julie E. Bauman, H H Chow

Institutions: National Institutes of Health, National Cancer Institute, Johns Hopkins University, Johns Hopkins Hospital, University of California, Irvine Medical Center, University of Southern California, Cedars-Sinai Medical Center, University of Arizona, University of Arizona Cancer Center

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Institutes of Health

OpenAlex ID: W4212869151

Cites:

Cited by: 2

Related to: 10